Alpha synuclein is transported into and out of the brain by the blood-brain barrier

Peptides

Volumn 62, Issue , 2014, Pages 197-202

  Sui, Yu Ting ^a   Bullock, Kristin M ^b   Erickson, Michelle A ^b   Zhang, Jing ^a   Banks, W A ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

Alpha synuclein; Blood brain barrier; LRP 1; p Glycoprotein; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MULTIDRUG RESISTANCE PROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; LRP1 PROTEIN, MOUSE; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; BLOOD BRAIN BARRIER; EFFUSION; INFLAMMATION; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; PROTEIN TRANSPORT; ANIMAL; CHEMICALLY INDUCED; HUMAN; LEWY BODY; METABOLISM; MORTALITY; PARKINSON DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ALPHA-SYNUCLEIN; ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; HUMANS; INFLAMMATION; LEWY BODIES; LIPOPOLYSACCHARIDES; LIPOPROTEINS, LDL; MICE; P-GLYCOPROTEIN; PARKINSON DISEASE; RECEPTORS, LDL; TUMOR SUPPRESSOR PROTEINS;

EID: 84909996967     PISSN: 01969781     EISSN: 18735169     Source Type: Journal    
DOI: 10.1016/j.peptides.2014.09.018     Document Type: Article

References (62)

1. Alexander GM, Schwartzman RJ, Grothusen JR, Gordon SW. Effect of plasma levels of large neutral amino acids and degree of parkinsonism on the blood-to-brain transport of levodopa in naive and MPTP parkinsonian monkeys. Neurology 1994;44:1491-9.
2. Banks WA, Clever CM, Farrell CL. Partial saturation and regional variation in the blood to brain transport of leptin in normal weight mice. Am J Physiol 2000;278:E1158-65.
3. Banks WA, Fasold MB, Kastin AJ. Measurement of efflux rate from brain to blood. In: Irvine GB, Williams CH, editors. Methods in Molecular Biology: Neuropeptides Protocols. Totowa, NJ: Humana Press; 1997. p. 353-60.
4. Banks WA, Kastin AJ. Modulation of the carrier-mediated transport of the Tyr-MIF-1 across the blood-brain barrier by essential amino acids. J Pharmacol Exp Ther 1986;239:668-72.
5. Banks WA, Kastin AJ. Quantifying carrier-mediated transport of peptides from the brain to the blood. In: Conn PM, editor. Methods in Enzymology, vol. 168. San Diego: Academic Press; 1989. p. 652-60.
6. Banks WA, Kastin AJ, Fischman AJ, Coy DH, Strauss SL. Carrier-mediated transport of enkephalins and N-Tyr-MIF-1 across blood-brain barrier. Am J Physiol 1986;251:E477-82.
7. Banks WA, Kastin AJ, Huang W, Jaspan JB, Maness LM. Leptin enters the brain by a saturable system independent of insulin. Peptides 1996;17:305-11.
8. Banks WA, Ortiz L, Plotkin SR, Kastin AJ. Human interleukin (IL) 1alpha, murine IL-1 alpha and murine IL-1 beta are transported from blood to brain in the mouse by a shared saturable mechanism. J Pharmacol Exp Ther 1991;259:988-96.
9. Banks WA, Robinson SM, Diaz-Espinoza R, Urayama A, Soto C. Transport of prion protein across the blood-brain barrier. Exp Neurol 2009;218:162-7.
10. Banks WA, Robinson SM, Verma S, Morley JE. Efflux of human and mouse amyloid β proteins 1-40 and 1-42 from brain: impairment in a mouse model of Alzheimer's disease. Neuroscience 2003;121:487-92.
11. Blasberg RG, Fenstermacher JD, Patlak CS. Transport of alpha-aminoisobutyric acid across brain capillary and cellular membranes. J Cereb Blood Flow Metab 1983;3:8-32.
12. Borghi R, Marchese R, Negro A, Marinelli L, Forloni G, Zaccheo D, et al. Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci Lett 2000;287:65-7.
13. Braidy N, Gai WP, Xu YH, Sachdev P, Guillemin GJ, Jiang XM, et al. Uptake and mitochondrial dysfunction of alpha-synuclein in human astrocytes, cortical neurons and fibroblasts. Transl neurodegener 2013;2:20.
14. Brightman MW, Reese TS. Junctions between intimately apposed cell membranes in the vertebrate brain. J Cell Biol 1969;40:648-77.
15. Carvey PM, Chang Q, Lipton JW, Ling Z. Prenatal exposure to the bacteriotoxin lipopolysaccharide leads to long-term losses of dopamine neurons in offspring: a potential, new model of Parkinson's disease. Front Biosci 2003;8:s826-37.
16. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004;364:1167-9.
17. Cirrito JR, Deane R, Fagan AM, Spinner ML, Parasadanian M, Finn MB, et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-β deposition in an Alzheimer disease mouse model. J Clin Invest 2005;115:3285-90.
18. Collinge J. Human prion diseases and bovine spongiform encephalopathy (BSE). Hum Mol Genet 1997;6:1699-705.
19. Cookson MR. The biochemistry of Parkinson's disease. Annu Rev Biochem 2005;74:29-52.
20. Deane R, Sagare A, Zlokovic B. The role of the cell surface LRP and soluble LRP in blood-brain barrier Aβ clearance in Alzheimer's disease. Curr Pharm Des 2008;14:1601-5.
21. Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 2004;43:333-44.
22. DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 2002;295:2264-7.
23. El-Agnaf OM, Salem SA, Paleologou KE, Cooper LJ, Fullwood NJ, Gibson MJ, et al. Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J 2003;17:1945-7.
24. El-Agnaf OM, Salem SA, Paleologou KE, Curran MD, Gibson MJ, Court JA, et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J 2006;20:419-25.
25. Erickson MA, Banks WA. Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease. J Cereb Blood Flow Metab 2013 [Epub ahead of print].
26. Eslamboli A, Romero-Ramos M, Burger C, Bjorklund T, Muzyczka N, Mandel RJ, et al. Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain: J Neurol 2007;130:799-815.
27. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain: J Neurol 1991;114(Pt 5):2283-301.
28. Fuchs J, Nilsson C, Kachergus J, Munz M, Larsson EM, Schule B, et al. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 2007;68:916-22.
29. Hartz AM, Bauer B, Fricker G, Miller DS. Rapid regulation of P-glycoprotein at the blood-brain barrier by endothelin-1. Mol Pharmacol 2004;66:387-94.
30. Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain: J Neurol 2010;133:713-26.
31. Kim SY, Buckwalter M, Soreq H, Vezzani A, Kaufer D. Blood-brain barrier dysfunction-induced inflammatory signaling in brain pathology and epileptogenesis. Epilepsia 2012;53(Suppl 6):37-44.
32. Kirik D, Annett LE, Burger C, Muzyczka N, Mandel RJ, Bjorklund A. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc Natl Acad Sci U S A 2003;100:2884-9.
33. Kisos H, Pukass K, Ben-Hur T, Richter-Landsberg C, Sharon R. Increased neuronal alpha-synuclein pathology associates with its accumulation in oligodendrocytes in mice modeling alpha-synucleinopathies. PLoS ONE 2012;7:e46817.
34. Kortekaas R, Leenders KL, van Oostrom JC, Vaalburg W, Bart J, Willemsen AT, et al. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 2005;57:176-9.
35. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998;18:106-8.
36. Lauwers E, Debyser Z, Van Dorpe J, De Strooper B, Nuttin B, Baekelandt V. Neuropathology and neurodegeneration in rodent brain induced by lentiviral vector-mediated overexpression of alpha-synuclein. Brain Pathol 2003;13:364-72.
37. Lee CG, Tang K, Cheung YB, Wong LP, Tan C, Shen H, et al. MDR1, the blood-brain barrier transporter, is associated with Parkinson's disease in ethnic Chinese. J Med Genet 2004;41:e60.
38. Lee HJ, Patel S, Lee SJ. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci 2005;25:6016-24.
39. Lee HJ, Suk JE, Patrick C, Bae EJ, Cho JH, Rho S, et al. Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem 2010;285:9262-72.
40. Lee PH, Lee G, Park HJ, Bang OY, Joo IS, Huh K. The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy. J Neural Transm 2006;113:1435-9.
41. Li Y, Li Y, Pang S, Huang W, Zhang A, Hawley RG, et al. Novel and functional ABCB1 gene variant in sporadic Parkinson's disease. Neurosci Lett 2014;566:61-6.
42. Lo Bianco C, Ridet JL, Schneider BL, Deglon N, Aebischer P. alpha-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc Natl Acad Sci U S A 2002;99:10813-8.
43. Miller DW, Hague SM, Clarimon J, Baptista M, Gwinn-Hardy K, Cookson MR, et al. Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology 2004;62:1835-8.
44. Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro TF, Pepivani I, et al. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 2008;213:315-25.
45. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher MG. alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011;10:230-40.
46. Ohtsuki S, Yamaguchi H, Kang YS, Hori S, Terasaki T. Reduction of L-type amino acid transporter 1 mRNA expression in brain capillaries in a mouse model of Parkinson's disease. Biol Pharm Bull 2010;33:1250-2.
47. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983;3:1-7.
48. Perry VH. The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease. Brain Behav Immun 2004;18:407-13.
49. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-7.
50. Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS, et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007;55:453-62.
51. Shi M, Liu CS, Cook TJ, Bullock KM, Zhao Y, Ginghina C, et al. Plasma exosomal alpha-synuclein is likely CNS-derived and increased in Parkinson's disease. Acta Neuropathol 2014 [Epub ahead of print].
52. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003;302:841.
53. Soto C, Kascsak RJ, Saborio GP, Aucouturier P, Wisniewski T, Prelli F, et al. Reversion of prion protein conformational changes by synthetic beta-sheet breaker peptides. Lancet 2000;355:192-7.
54. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett 1998;251:205-8.
55. St Martin JL, Klucken J, Outeiro TF, Nguyen P, Keller-McGandy C, Cantuti-Castelvetri I, et al. Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. J Neurochem 2007;100:1449-57.
56. Thomas B, Beal MF. Parkinson's disease. Hum Mol Genet 2007;16(Spec. No. 2):R183-94.
57. Tokuda T, Qureshi MM, Ardah MT, Varghese S, Shehab SA, Kasai T, et al. Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 2010;75:1766-72.
58. Tokuda T, Salem SA, Allsop D, Mizuno T, Nakagawa M, Qureshi MM, et al. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun 2006;349:162-6.
59. Wilhelmus MM, Bol JG, Van Haastert ES, Rozemuller AJ, Bu G, Drukarch B, et al. Apolipoprotein E and LRP1 increase early in Parkinson's disease pathogenesis. Am J Pathol 2011;179:2152-6.
60. Yamada M, Iwatsubo T, Mizuno Y, Mochizuki H. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. J Neurochem 2004;91:451-61.
61. Yasuda T, Miyachi S, Kitagawa R, Wada K, Nihira T, Ren YR, et al. Neuronal specificity of alpha-synuclein toxicity and effect of Parkin co-expression in primates. Neuroscience 2007;144:743-53.
62. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004;55:164-73.